Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Common Equity: 2014-2025

Historic Common Equity for AC Immune (ACIU) over the last 12 years, with Sep 2025 value amounting to $214.5 million.

  • AC Immune's Common Equity fell 23.91% to $214.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.5 million, marking a year-over-year decrease of 23.91%. This contributed to the annual value of $214.5 million for FY2025, which is N/A change from last year.
  • Latest data reveals that AC Immune reported Common Equity of $214.5 million as of FY2025, which was up 81,283.85% from $263,592 recorded in FY2024.
  • Over the past 5 years, AC Immune's Common Equity peaked at $253.9 million during FY2021, and registered a low of $206,096 during FY2023.
  • In the last 3 years, AC Immune's Common Equity had a median value of $263,592 in 2024 and averaged $71.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 99.88% in 2023, then rose by 27.90% in 2024.
  • Over the past 5 years, AC Immune's Common Equity (Yearly) stood at $253.9 million in 2021, then plummeted by 30.90% to $175.4 million in 2022, then slumped by 99.88% to $206,096 in 2023, then rose by 27.90% to $263,592 in 2024, then reached $214.5 million in 2025.